Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (3799)	5/2/1998 9:10:00 PM
From: CalculatedRisk	Read Replies (2) \| Respond to of 7041

Linda, thank you for providing this poster information. The information is somewhat confusing (to me<g>): 1) To be eligible for the study, the men had "minimal erectile dysfunction", yet at the endpoint, if successful, they had "mid-to-moderate dysfunction". This sounds like the patient's conditions worsened! Is this a presentation error? 2) I'm not familiar with drug testing. What is meant by "crossover design"? Thanks again for this post! Regards, Bill